Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Surgical Pathology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Karzinoide tumoren des dunndarms.Frankf Z Pathol. 1907; 1: 426-432
- Siegfried Oberndorfer: origins and perspectives of carcinoid tumors.Hum Pathol. 2004; 35: 1440-1451
- Evolution of the diffuse neuroendocrine system: clear cells and cloudy origins.Neuroendocrinology. 2006; 84: 69-82
- Oberndorfer and his successors: from carcinoid to neuroendocrine carcinoma.Endocr Pathol. 2007; 18: 141-144
- Neuroendocrine neoplasms: historical background and terminologies.in: Asa S.L. La Rosa S. Mete O. The spectrum of neuroendocrine neoplasia: a practical approach to diagnosis, classification and therapy. Springer International Publishing, Cham, Switzerland2021: 1-14
- Identification, morphology, and secretory products of the pulmonary endocrine system.in: Pulmonary endocrine pathology: endocrine cells and endocrine tumours of the lung. Butterworth-Heinemann Ltd, Oxford (United Kingdom)1992: 6-24
- Overview of the 2022 WHO classification of neuroendocrine neoplasms.Endocr Pathol. 2022; 33: 115-154
- Endocrine and neuroendocrine tumours.5th edition. IARC Press, Lyon2022
- A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.Mod Pathol. 2018; 31: 1770-1786
- Lung neuroendocrine neoplasms: recent progress and persistent challenges.Mod Pathol. 2022; 35: 36-50
- The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.Am J Surg Pathol. 2015; 39: 683-690
- Genetic and epigenetic alterations in pancreatic neuroendocrine tumors.J Gastrointest Oncol. 2020; 11: 567-577
- Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?.Hum Pathol. 2020; 96: 8-33
- Algorithmic approach to neuroendocrine tumors in targeted biopsies: practical applications of immunohistochemical markers.Cancer Cytopathol. 2016; 124: 871-884
- Thoracic tumours.5th ed. IARC Press, Lyon2022
- Digestive system tumours.5th ed. IARC Press, Lyon2019
- Head and neck tumours.5th ed. IARC Press, Lyon2022
- Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice.J Thorac Oncol. 2014; 9: 273-284
- Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States.JAMA Oncol. 2017; 3: 1335-1342
- The 2019 WHO classification of tumours of the digestive system.Histopathology. 2020; 76: 182-188
- What is new in the 2019 World Health Organization (WHO) Classification of Tumors of the Digestive System: review of selected updates on neuroendocrine neoplasms, appendiceal tumors, and molecular testing.Arch Pathol Lab Med. 2020; 145: 664-677
- Update from the 5th edition of the World Health Organization Classification of Head and Neck Tumors: overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms.Head Neck Pathol. 2022; 16: 123-142
- Morphologic variants of pancreatic neuroendocrine tumors: clinicopathologic analysis and prognostic stratification.Endocr Pathol. 2020; 31: 239-253
- Pancreatic high-grade neuroendocrine neoplasms in the Korean population: a multicenter study.Cancer Res Treat. 2020; 52: 263-276
- Pathologic analysis of carcinoids: histologic re-evaluation of 62 cases.Cancer. 1971; 28: 990-998
- WHO classification of tumours of the digestive system.4th ed. IARC Press, Lyon2010
- Revised classification of neuroendocrine tumours of the lung, pancreas and gut.Virchows Archiv A Pathol Anat. 1995; 425
- Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.J Clin Oncol. 2002; 20: 2633-2642
- Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.Ann Oncol. 2013; 24: 152-160
- Gastroenteropancreatic high-grade neuroendocrine carcinoma.Cancer. 2014; 120: 2814-2823
- RB loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: a Japanese multicenter pancreatic NEN-G3 study.Clin Cancer Res. 2017; 23: 4625-4632
- A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas.Am J Surg Pathol. 2016; 40: 1192-1202
- Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas.Clin Cancer Res. 2016; 22: 1011-1017
- The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.Endocr Relat Cancer. 2021; 29: 1-14
- Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.Endocr Rel Cancer. 2015; 22: 657-664
- Concordance between the Ki-67 index cutoff value of 55% and differentiation in neuroendocrine tumor and neuroendocrine carcinoma in grade 3 pancreatic neuroendocrine neoplasms.Pancreas. 2020; 49: 1378-1382
- Are G3 ENETS neuroendocrine neoplasms heterogeneous?.Endocr Relat Cancer. 2013; 20: 649-657
- Treatment outcomes of patients with G3 neuroendocrine neoplasms [abstract only].J Clin Oncol. 2020; 38: 622
- Treatment response and outcomes of grade 3 pancreatic neuroendocrine neoplasms based on morphology: well differentiated versus poorly differentiated.Pancreas. 2017; 46: 296-301
- High-grade poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: from morphology to proliferation and back.Endocr Pathol. 2014; 25: 193-198
- Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort.Sci Rep. 2021; 11: 17947
- Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3.Hum Pathol. 2018; 77: 70-79
- WHO classification of tumours of endocrine organs.4th ed. IARC Press, Lyon2017
- Competitive testing of the WHO 2010 versus the WHO 2017 grading of pancreatic neuroendocrine neoplasms: data from a large international cohort study.Neuroendocrinology. 2018; 107: 375-386
- Borderline” neuroendocrine carcinomas of the lung are clinically and genomically distinct from large-cell neuroendocrine carcinoma [abstract only].Mod Pathol. 2016; 29: 467-488
- Endobronchial large-cell neuroendocrine carcinoma.Pathol Oncol Res. 2003; 9: 198-200
- Next-generation sequencing of pulmonary large-cell neuroendocrine carcinoma reveals small-cell carcinoma-like and non-small-cell carcinoma-like subsets.Clin Cancer Res. 2016; 22: 3618-3629
- Two cases of lung neuroendocrine carcinoma with carcinoid morphology.Diagn Pathol. 2019; 14: 104
- Pulmonary neuroendocrine neoplasms with well differentiated morphology and high proliferative activity: illustrated by a case series and review of the literature.Lung Cancer. 2020; 150: 152-158
- Clinic and genetic similarity assessments of atypical carcinoid, neuroendocrine neoplasm with atypical carcinoid morphology and elevated mitotic count and large-cell neuroendocrine carcinoma.BMC Cancer. 2022; 22: 321
- Transcriptomic data helps refining classification of pulmonary carcinoid tumors with increased mitotic counts.Mod Pathol. 2020; 33: 1712-1721
- High-grade neuroendocrine carcinoma of the lung with carcinoid morphology: a study of 12 cases.Am J Surg Pathol. 2017; 41: 263-270
- Small-cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens.Am J Surg Pathol. 2002; 26: 1184-1197
- Advances in neuroendocrine lung tumors.Ann Oncol. 2010; 21: vii65-vii71
- Update on small-cell carcinoma and its differentiation from squamous cell carcinoma and other non-small-cell carcinomas.Mod Pathol. 2012; 25: S18-S30
- Pancreatic neuroendocrine tumors: surgical outcomes and survival analysis.Am J Surg. 2021; 221: 529-533
- Outcomes after surgical resection of pulmonary carcinoid tumors.J Cardiothorac Surg. 2016; 11: 35
- Role of somatostatin receptor in pancreatic neuroendocrine tumor development, diagnosis, and therapy.Front Endocrinol (Lausanne). 2021; 12: 679000
- Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2020; 31: 844-860
- Peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors: recent insights.Onco Targets Ther. 2020; 13: 3545-3555
- Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2021; 32: 439-451
- The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5.Exp Ther Med. 2021; 22: 1-9
- Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2––clinical implications.J Cell Mol Med. 2010; 14: 2585-2591
- Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.J Clin Oncol. 2009; 27: 4656-4663
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors.N Engl J Med. 2014; 371: 224-233
- Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases.Semin Intervent Radiol. 2013; 30: 28-38
- GEP-NETs update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs.Eur J Endocrinol. 2015; 172: R151-R166
- Indications of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic and pulmonary neuroendocrine tumors: an updated review.J Clin Med. 2021; 10: 1267
- Systematic review and meta-analysis on the role of chemotherapy in advanced and metastatic neuroendocrine tumor (NET).PLoS ONE. 2016; 11: e0158140
- Biologics in gastrointestinal and pancreatic neuroendocrine tumors.J Gastrointest Oncol. 2017; 8: 457-465
- Everolimus for advanced pancreatic neuroendocrine tumors.N Engl J Med. 2011; 364
- Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.Ann Oncol. 2017; 28: 339-343
- Small-cell lung cancer, version 2.2022, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2021; 19: 1441-1464
- Update on the biology, management, and treatment of small-cell lung cancer (SCLC).Front Oncol. 2020; 10: 1074
- Current treatment strategies and future directions for extrapulmonary neuroendocrine carcinomas: a review.JAMA Oncol. 2021; 7: 759-770
- Clinical and therapeutic aspects of extrapulmonary small-cell carcinoma.Cancer Treat Rev. 2009; 35: 228-236
- Surgery for limited-stage small-cell lung cancer.Cochrane Database Syst Rev. 2017; 2017: CD011917
- Large-cell neuro-endocrine carcinoma of the lung: current treatment options and potential future opportunities.Front Oncol. 2021; 11: 650293
- Management of large-cell neuroendocrine carcinoma.Front Oncol. 2021; 11: 653162
- Large-cell neuroendocrine carcinoma of the lung: surgical management.Thorac Surg Clin. 2014; 24: 305-311
- Outcomes for surgery in large-cell lung neuroendocrine cancer.J Thorac Oncol. 2019; 14: 2143-2151
- Treatment of advanced-stage large-cell neuroendocrine cancer (LCNEC) of the lung: a tale of two diseases.Front Oncol. 2021; 11
- Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome.Clin Cancer Res. 2018; 24: 33-42
- Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.Nat Commun. 2018; 9: 1048
- Genomic profiling of large-cell neuroendocrine carcinoma of the lung.Clin Cancer Res. 2017; 23: 757-765
- Multiple faces of pulmonary large-cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis.Transl Lung Cancer Res. 2020; 9
- Prevalence of TP-53/RB-1 co-mutation in large-cell neuroendocrine carcinoma.Front Oncol. 2021; 11: 653153
- The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma.Clin Cancer Res. 2020; 26: 892-901
- Small-cell and large-cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.Am J Surg Pathol. 2012; 36: 173-184
- The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets.Nat Commun. 2021; 12: 4612
- Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.J Pathol. 2017; 241: 488-500
- A genomics-based classification of human lung tumors.Sci Transl Med. 2013; 5: 209ra153
- Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.Am J Pathol. 1998; 153: 1089-1098
- Molecular pathology and genetics of pancreatic endocrine tumours.J Mol Endocrinol. 2012; 49: R37-R50
- Chromosomal alterations detected by comparative genomic hybridization in nonfunctioning endocrine pancreatic tumors.Cancer Genet Cytogenet. 2005; 156: 23-30
- Whole-genome landscape of pancreatic neuroendocrine tumours.Nature. 2017; 543: 65-71
- DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.Science. 2011; 331: 1199-1203
- MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases.Endocr Relat Cancer. 2010; 17: 771-783
- Next-generation sequencing (NGS) in advanced well differentiated pancreatic neuroendocrine tumors (WD pNETs): a study using MSK-IMPACT.J Clin Oncol. 2016; 34: e15661
- Altered telomeres in tumors with ATRX and DAXX mutations.Science. 2011; 333: 425
- Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.Gastroenterology. 2014; 146: 453-460.e5
- Alternative lengthening of telomeres in primary pancreatic neuroendocrine tumors is associated with aggressive clinical behavior and poor survival.Clin Cancer Res. 2017; 23: 1598-1606
- Alternative lengthening of telomeres and loss of DAXX/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors.Clin Cancer Res. 2017; 23: 600-609
- DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.Oncotarget. 2017; 8: 49796-49806
- ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup.Nat Commun. 2018; 9: 4158
- Prognostic biomarkers in pancreatic neuroendocrine tumors.Cancer Cytopathol. 2021; 129: 841-843
- New insights into the molecular characteristics of pulmonary carcinoids and large-cell neuroendocrine carcinomas, and the impact on their clinical management.J Thorac Oncol. 2018; 13: 752-766
- Exploring the molecular and biological background of lung neuroendocrine tumours.J Thorac Dis. 2019; 11: S1194-S1198
- Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids.Nat Commun. 2014; 27: 3518
- Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung.Hum Mol Genet. 1997; 6: 2285-2290
- MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids.J Clin Endocrinol Metab. 2014; 99: E374-E378
- Molecular alterations of neuroendocrine tumours of the lung.Histopathology. 2018; 72: 142-152
- Comprehensive genomic profiles of small-cell lung cancer.Nature. 2015; 524: 47-53
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.Nat Genet. 2012; 44: 1104-1110
- Small-cell lung carcinoma subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: comprehensive immunohistochemical and histopathologic characterization.J Thorac Oncol. 2020; 15: 1823-1835
- Molecular subtypes of small-cell lung cancer: a synthesis of human and mouse model data.Nat Rev Cancer. 2019; 19: 289-297
- ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs.Cell Rep. 2016; 16: 1259-1272
- Prognostic implications of molecular subtypes in primary small-cell lung cancer and their correlation with cancer immunity.Front Oncol. 2022; 12: 779276
- An algorithmic immunohistochemical approach to define tumor type and assign site of origin.Adv Anat Pathol. 2020; 27: 114-163
- INSM1 demonstrates superior performance to the individual and combined use of synaptophysin, chromogranin and CD56 for diagnosing neuroendocrine tumors of the thoracic cavity.Am J Surg Pathol. 2017; 41: 1561-1569
- INSM1: a novel immunohistochemical and molecular marker for neuroendocrine and neuroepithelial neoplasms.Am J Clin Pathol. 2015; 144: 579-591
- Clinical routine application of the second-generation neuroendocrine markers ISL2, INSM1, and secretagogin in neuroendocrine neoplasia: staining outcomes and potential clues for determining tumor origin.Endocr Pathol. 2020; 31: 401-410
- Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry.Adv Anat Pathol. 2013; 20: 285-314
- Neuroendocrine tumors of unknown primary: is the primary site really not known?.JAMA Surg. 2014; 149: 889-890
- Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?.Tumori. 2011; 97: 564-567
- Professional practices and diagnostic issues in neuroendocrine tumour pathology: results of a prospective one-year survey among French pathologists (the PRONET study).Neuroendocrinology. 2017; 105: 67-76
- PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms.Am J Surg Pathol. 2012; 36: 737-743
- CDX2 as a marker for neuroendocrine tumors of unknown primary sites.Endocr Pathol. 2004; 15: 247-252
- ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin.Mod Pathol. 2013; 26: 995-1003
- Clusterin in neuroendocrine epithelial neoplasms: absence of expression in a well-differentiated tumor suggests a jejunoileal origin.Appl Immunohistochem Mol Morphol. 2018; 26: 94-100
- Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.Am J Surg Pathol. 2010; 34: 300-313
- Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.Am J Surg Pathol. 2013; 37: 1671-1677
- Grading of neuroendocrine neoplasms: mitoses and Ki-67 are both essential.Neuroendocrinology. 2014; 100: 221-227
- Heterogeneity of mitotic activity in breast cancer.Histopathology. 1996; 29: 421-428
- Comparison of cell growth in different parts of breast cancers.Histopathology. 1990; 17: 505-509
- Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.Am J Surg Pathol. 2011; 35: 853-860
- Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors.Mod Pathol. 2009; 22: 273-281
- Counting mitoses: SI(ze) matters.Mod Pathol. 2021; 34: 1651-1657
- Are we counting mitoses correctly?.Ann Diagn Pathol. 2013; 17: 536-539
- A proposal for the adoption of a uniform metrical system for mitosis counting.Int J Surg Pathol. 2005; 13: 157-159
- Grading and prognostication of neuroendocrine tumors of the pancreas: a comparison study of Ki67 and PHH3.J Histochem Cytochem. 2017; 65: 399-405
- Identification of phosphohistone H3 cutoff values corresponding to original WHO grades but distinguishable in well-differentiated gastrointestinal neuroendocrine tumors.Biomed Res Int. 2018; 2018: e1013640
- Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies.Mod Pathol. 2015; 28: 686-694
- Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.Am J Surg Pathol. 2012; 36: 1761-1770
- Digital image analysis of the proliferation markers Ki67 and phosphohistone H3 in gastroenteropancreatic neuroendocrine neoplasms: accuracy of grading compared with routine manual hot spot evaluation of the Ki67 index.Appl Immunohistochem Mol Morphol. 2021; 29: 499-505
- Potential pitfalls in diagnostic digital image analysis: experience with Ki-67 and PHH3 in gastrointestinal neuroendocrine tumors.Pathol Res Pract. 2020; 216: 152753
- Ki67 quantitative interpretation: insights using image analysis.J Pathol Inform. 2019; 10: 8
- Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors.Mod Pathol. 2012; 25: 1258-1264
- Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach.Virchows Arch. 2012; 460: 299-308
- Partitioning of bronchopulmonary carcinoids in two different prognostic categories by Ki-67 score.Front Endocrinol (Lausanne). 2011; 2: 20
- ERCC1 and Ki67 in small-cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.J Thorac Oncol. 2010; 5: 453-459
- Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact.Am J Clin Pathol. 2005; 123: 874-878
Article info
Publication history
Published online: December 09, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
